Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Abeona Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RDEA PILOT PROGRAM PROVIDES SPONSORS ENHANCED COMMUNICATION AND COLLABORATION WITH FDA TO ACCELERATE DEVELOPMENT OF RARE DISEASE THERAPIES RDEA PILOT PROGRAM PROVIDES SPONSORS ENHANCED COMMUNICATION AND COLLABORATION WITH FDA TO ACCELERATE DEVELOPMENT OF RARE DISEASE THERAPIES

ABEONA THERAPEUTICS ANNOUNCES ABO-503 GENE THERAPY FOR X-LINKED RETINOSCHISIS (XLRS) SELECTED BY FDA FOR RARE DISEASE ENDPOINT ADVANCEMENT (RDEA) PILOT PROGRAM

CLEVELAND, OHIO AND AURORA, COLO., OCT. 08, 2025 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) AND CHILDREN'S HOSPITAL COLORADO TODAY ANNOUNCED ACTIVATION OF CHILDREN'S COLORADO AS THE NEWEST QUALIFIED TREATMENT CENTER (QTC) FOR ZEVASKYN (PRADEMAGENE ZAMIKERACEL) GENE-MODIFIED CELLULAR SHEETS. THIS FIRST-OF-ITS-KIND THERAPY IS FDA-APPROVED TO TREAT WOUNDS IN ADULT AND PEDIATRIC PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB). CHILDREN'S COLORADO IN AURORA, CO, ONE OF THE PIONEERING INSTITUTIONS THAT PROVIDE ADVANCED LEVELS OF CARE FOR PEOPLE WITH EPIDERMOLYSIS BULLOSA (EB), HAS COMPLETED QTC START-UP ACTIVITIES ENABLING IT TO BEGIN PATIENT IDENTIFICATION FOR SCHEDULING OF ZEVASKYN TREATMENT.

ABEONA THERAPEUTICS AND CHILDREN'S HOSPITAL COLORADO ANNOUNCE NEWEST TREATMENT CENTER FOR ZEVASKYN GENE THERAPY

CLEVELAND, OCT. 01, 2025 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ABEONA THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

CLEVELAND, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CLEVELAND, AUG. 29, 2025 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED THAT MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN SEPTEMBER 2025:

ABEONA THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

- RECEIVED FDA APPROVAL FOR ZEVASKYN (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY AUTOLOGOUS CELL-BASED GENE THERAPY FOR THE TREATMENT OF WOUNDS IN ADULT AND PEDIATRIC PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) -

ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATES

CLEVELAND, AUG. 01, 2025 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

BERWYN, PA., JULY 29, 2025 (GLOBE NEWSWIRE) -- ASCELLAHEALTH, A GLOBAL PARTNER DELIVERING CUSTOMIZABLE SOLUTIONS TO SUPPORT THE SPECIALTY PHARMACEUTICAL INDUSTRY, HIGHLIGHTS THE VALUE OF ITS HUB PARTNERSHIP WITH ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) IN THE SUCCESSFUL PRE-AND-POST LAUNCH COMMERCIALIZATION OF ZEVASKYN, AN FDA-APPROVED CELL-BASED GENE THERAPY.

ASCELLAHEALTH HUB PARTNERSHIP WITH ABEONA THERAPEUTICS SUPPORTS LAUNCH SUCCESS OF NOVEL CELL-BASED GENE THERAPY AND ACCESS TO TREATMENT FOR RARE DISEASE PATIENTS

- LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD IS READY TO ACCEPT PATIENTS FOR ZEVASKYN TREATMENT - - ABEONA THERAPEUTICS  AND STANFORD MEDICINE CONDUCTED RESEARCH COLLABORATION FOR MORE THAN A DECADE, CULMINATING IN U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF ZEVASKYN IN APRIL 2025 - - ZEVASKYN IS THE ONLY FDA-APPROVED THERAPY TO TREAT RDEB WOUNDS WITH A SINGLE APPLICATION - CLEVELAND, JULY 15, 2025 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED ACTIVATION OF THE NEWEST QUALIFIED TREATMENT CENTER (QTC) FOR FDA-APPROVED ZEVASKYN (PRADEMAGENE ZAMIKERACEL) GENE-MODIFIED CELLULAR SHEETS. THIS FIRST-OF-ITS-KIND THERAPY, AN OUTCOME OF A DECADE OF RESEARCH BY ABEONA AND TWO DECADES OF RESEARCH AT STANFORD MEDICINE, WHERE THE TECHNOLOGY ORIGINATED, WILL BE USED TO TREAT WOUNDS IN ADULT AND PEDIATRIC PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB).

ZEVASKYN GENE THERAPY NOW AVAILABLE AT NEW QUALIFIED TREATMENT CENTER IN SAN FRANCISCO BAY AREA

MINNEAPOLIS , JULY 14, 2025 /PRNEWSWIRE/ -- BIO-TECHNE CORPORATION (NASDAQ: TECH) TODAY ANNOUNCED THAT ITS SIMPLE WESTERN TECHNOLOGY PLAYED A KEY ROLE IN SUPPORTING THE FDA APPROVAL OF ZEVASKYN (PRADEMAGENE ZAMIKERACEL), THE FIRST AUTOLOGOUS CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB), DEVELOPED BY ABEONA THERAPEUTICS (NASDAQ: ABEO). THROUGHOUT CLINICAL DEVELOPMENT, SIMPLE WESTERN ENABLED PRECISE IDENTIFICATION AND QUANTIFICATION OF COLLAGEN VII, A COMPLEX THERAPEUTIC TARGET CRITICAL TO ZEVASKYN'S POTENCY, SUPPORTING LOT RELEASE TESTING FOR THE VIRAL VECTOR AND THE CELL THERAPY IN A GMP SETTING.

BIO-TECHNE'S SIMPLE WESTERN TECHNOLOGY UTILIZED IN RECENT FDA APPROVAL OF ZEVASKYN CELL-BASED GENE THERAPY

CASH RESOURCES TOTALED APPROXIMATELY $225 MILLION AS OF JUNE 30, 2025 CASH RESOURCES TOTALED APPROXIMATELY $225 MILLION AS OF JUNE 30, 2025

ABEONA THERAPEUTICS CLOSES SALE OF RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR $155 MILLION

ABEONA WILL RECEIVE A LICENSE PAYMENT AND POTENTIAL DEVELOPMENT, REGULATORY, AND SALES MILESTONES, AND ROYALTIES ABEONA WILL RECEIVE A LICENSE PAYMENT AND POTENTIAL DEVELOPMENT, REGULATORY, AND SALES MILESTONES, AND ROYALTIES

Abeona Therapeutics Inc.

ABEO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Abeona Therapeutics Inc.

ABEO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ABEO